Recent events

Aurobindo Pharma acquires Khandelwal Laboratories' non-oncology prescription business for Rs 325 crore

Aurobindo Pharma, through its wholly owned subsidiary Auro Pharma Limited, acquired the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd on a going concern, slump sale basis for a cash consideration of Rs 325 crore, effective January 1, 2026. The acquired business comprises 23 established brands across 67 SKUs and nine pipeline products in pain management and anti-infective segments, with a turnover of Rs 113.5 crore, and is supported by a field force of approximately 470 personnel and over 1,600 stockists across India.